绥美凯的效果怎么样呢？

It is composed of three ingredients: DTG (DTG) + Abacavir (ABC) + Lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. Today we will learn about the effect of Suimeikai?

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance. 

Inbec has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the lifespans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time, on the Chinese market. The approval of Inbec fills this gap and meets the urgent need for convenient medication use by doctors and patients."

In 2018, GSK announced the launch of the integrase DTG (Inbec) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. Inbec uses DTG, an integrase inhibitor, as the core drug, and combines it with abacavir and lamivudine as a treatment plan. It is made into a single-tablet treatment and promoted, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

The above is the effect content, I hope it can help you!